Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38894   clinical trials with a EudraCT protocol, of which   6392   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-005180-27
    Sponsor's Protocol Code Number:1517-CL-0608
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-03-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-005180-27
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the
    Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic
    Kidney Disease Patients not on Dialysis
    Studio di fase 3, randomizzato, in doppio cieco, controllato con placebo sull’efficacia e la sicurezza di FG-4592 per il trattamento dell’anemia in pazienti affetti da malattia renale cronica non dializzati
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients
    FG-4592 nel trattamento dell’anemia in pazienti affetti da malattia renale cronica non dializzati
    A.4.1Sponsor's protocol code number1517-CL-0608
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstellas Pharma Europe B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Europe B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstellas Pharma Europe B.V.
    B.5.2Functional name of contact pointService Desk - Global Clinical Dev.
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 BE
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31715455050
    B.5.5Fax number+31715455501
    B.5.6E-mailcontact@nl.astellas.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code FG-4592 - 20 mg
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNASP1517
    D.3.9.1CAS number 808118-40-3
    D.3.9.2Current sponsor codeFG-4592
    D.3.9.3Other descriptive nameASP1517
    D.3.9.4EV Substance CodeSUB89572
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code FG-4592 - 50 mg
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNASP1517
    D.3.9.1CAS number 808118-40-3
    D.3.9.2Current sponsor codeFG-4592
    D.3.9.3Other descriptive nameASP1517
    D.3.9.4EV Substance CodeSUB89572
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code FG-4592 - 100 mg
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNASP1517
    D.3.9.1CAS number 808118-40-3
    D.3.9.2Current sponsor codeFG-4592
    D.3.9.3Other descriptive nameASP1517
    D.3.9.4EV Substance CodeSUB89572
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Anemia in CKD patients not on dialysis
    Anemia in pazienti con insufficenza renale cronica non dializzati
    E.1.1.1Medical condition in easily understood language
    Anemia in patients with chronic kidney disease
    Anemia in pazienti con insufficenza renale cronica
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 15.1
    E.1.2Level LLT
    E.1.2Classification code 10002272
    E.1.2Term Anemia
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of FG-4592 in the treatment of anemia in nondialysis
    Chronic Kidney Disease (CKD) subjects.
    L’obiettivo primario di questo studio è valutare l’efficacia di FG-4592 nel trattamento dell’anemia in soggetti affetti da malattia renale cronica (CKD) non dializzati.
    E.2.2Secondary objectives of the trial
    - To evaluate the safety of FG-4592.
    - To evaluate health-related quality of life benefit.
    - To evaluate the need for rescue therapy. (RBC transfusion, ESA, or IV
    Iron)
    • Valutare la sicurezza di FG-4592 nel trattamento dell’anemia in soggetti affetti da CKD non dializzati.
    • Valutare i benefici del trattamento con FG-4592 in termini di qualità di vita correlata alla salute (HRQoL) in soggetti affetti da anemia da CKD.
    • Valutare la necessità di ricorrere a terapia di salvataggio: trasfusione di eritrociti (RBC), farmaco stimolante l’eritropoiesi (ESA) o ferro endovenoso (EV).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subject is eligible for the study if all of the following apply:
    - Age ≥ 18 years
    - Diagnosis of chronic kidney disease, with Kidney Disease Outcomes
    Quality Initiative (KDOQI) Stage 3, 4 or 5, not receiving dialysis; with
    an eGFR <60 mL/min/1.73 m2 estimated using the abbreviated 4-
    variable Modification of Diet in Renal Disease (MDRD) equation.
    - Mean of the three most recent Hb values during the Screening period,
    obtained at least 4 days apart, must be ≤10.0 g/dL, with a difference of
    ≤1.0 g/dL between the highest and the lowest values.
    - Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3
    x upper limit of normal (ULN), and total bilirubin (TBL) ≤1.5 x ULN.
    - Body weight of 45.0 kg up to a maximum of 160.0 kg.
    •L’età del soggetto deve essere > 18 anni.
    •Al soggetto è stata diagnosticata una malattia renale cronica, con Stadio 3, 4 o 5 secondo la KDOQI (Kidney Disease Outcomes Quality Initiative) e attualmente non è in dialisi; il soggetto presenta un eGFR <60 ml/min/1,73 m2 stimato usando la versione abbreviata a 4 variabili dell’equazione MDRD (Modification of Diet in Renal Disease).
    •La media dei tre valori più recenti di Hb del soggetto durante il Periodo di screening, ottenuti a distanza di almeno 4 giorni, deve essere ≤10,0 g/dl, con una differenza ≤1,0 g/dl tra il valore massimo e quello minimo. L’ultimo valore di Hb deve risalire a non oltre 10 giorni prima della randomizzazione.
    •I livelli di alanino aminotransferasi (ALT) e aspartato aminostransferasi (AST) del soggetto sono ≤3 volte il limite superiore di normalità (ULN) e la bilirubina totale (TBL) è ≤1,5 volte l’ULN.
    •Il peso corporeo del soggetto è compreso tra 45,0 kg e un massimo di 160,0 kg.
    E.4Principal exclusion criteria
    - Any ESA treatment within 12 weeks prior to randomization.
    - More than one dose of IV iron within 12 weeks prior to randomization.
    - RBC transfusion within 8 weeks prior to randomization.
    - Chronic inflammatory disease that could impact erythropoiesis.
    XML File Identifier: AHAtHeXM5hXsCCKUy2I1LxAe1k8=
    Page 18/29
    - Myocardial infarction, acute coronary syndrome, stroke, seizure, or a
    thrombotic/thromboembolic event (e.g., pulmonary embolism) within 12
    weeks prior to randomization.
    - Two or more blood pressure values of systolic BP≥150 mmHg or
    diastolic BP≥95mmHg within 2 weeks prior to randomization.
    1. Il soggetto è stato trattato con un ESA nelle 12 settimane precedenti la randomizzazione.
    2. Il soggetto ha ricevuto più di una dose di ferro EV nelle 12 settimane precedenti la randomizzazione.
    3. Il soggetto ha ricevuto una trasfusione di eritrociti nelle 8 settimane precedenti la randomizzazione.
    4. Il soggetto soffre di una patologia infiammatoria cronica che potrebbe avere effetti sull’eritropoiesi
    5. È nota nel soggetto la presenza di scompenso cardiaco congestizio di Classe III o IV secondo la New York Heart Association.
    6. Due o più misurazioni della PA sistolica ≥150 mmHg o della PA diastolica ≥95mmHg nelle 2 settimane precedenti la randomizzazione.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable is Hb response.
    La variabile di efficacia primaria è la risposta dell’Hb
    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to and including week 24
    Fino alla settimana 24 inclusa
    E.5.2Secondary end point(s)
    - Hb change from baseline to the average of weeks 28-36
    - LDL Change from baseline to the average of weeks 12-28
    - Physical Functioning subscore and Vitality subscore change from
    baseline to the average of week 12-28.
    - BP effect
    - Occurence of hypertension
    - Having received rescue therapy (composite of RBC transfusions, ESA
    use and IV iron)
    • Mantenimento dell’Hb: variazione dell’Hb dal basale alla media delle settimane 28-36, senza aver ricevuto una terapia di salvataggio nelle 6 settimane che precedono e durante questo periodo di valutazione di 8 settimane.
    • Variazione del colesterolo LDL (lipoproteina a bassa densità) dal basale alla media delle settimane 12-28.
    • Variazione del sottopunteggio sulla funzionalità fisica (PF) del questionario SF-36 dal basale alla media delle settimane 12-28.
    • Variazione del sottopunteggio sulla vitalità (VT) del questionario SF-36 dal basale alla media delle settimane 12-28.
    • Effetto sulla pressione arteriosa
    • Variazione della pressione arteriosa media (MAP) dal basale alla media delle settimane 20-28.
    • Occorrenza di ipertensione (definita come una PA sistolica > 170 mmHg o una PA diastolica > 110 mmHg misurata e un aumento rispetto al basale ≥15 mmHg [PA diastolica] o ≥20 mmHg [PA sistolica] in occasione di 2 visite consecutive) o intensificazione della terapia antipertensiva rispetto al basale
    • Somministrazione della terapia di salvataggio (variabile composita di trasfusioni di eritrociti, utilizzo di ESA e ferro EV).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 12 to week 28
    Dalla settimana 12 alla settimana 28
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA93
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Bulgaria
    France
    Hungary
    Italy
    Poland
    Romania
    Russian Federation
    Serbia
    Spain
    Turkey
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 420
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 180
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 540
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-05-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-05-08
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA